Search results
Jun 20, 2013 · 563 views 10 years ago. NCI's Pat Steeg makes a case for redesigning clinical trials to do "phase II randomized metastasis-prevention trials." Currently, phase I and phase II clinical trials...
- 5 min
- 566
- Katherine OBrien
Aug 3, 2023 · It was when I visited Lance Liotta’s lab at the NCI in the mid-1980s that I met his postdoc, Patricia Steeg. Pat had hypothesized the existence of a class of genes that block metastasis. As readers of Cancer & Metastasis Reviews already know, she discovered Nm23 (non-metastatic clone 23; now designated NME1) [ 1 ].
Jun 23, 2013 · 0. 199 views 10 years ago. Here Dr. Steeg explains how a clinical trial for metastatic breast cancer prevention might work. She further cited an FDA presentation that suggests this might be an...
Patricia Steeg - Deputy Chief, Women's Malignancies Branch, Center for Cancer Research, NCI - NCI | LinkedIn. Deputy Chief, Women's Malignancies Branch, Center for Cancer Research, NCI at NC....
- 3
- 5
- NCI
- Bethesda, Maryland, United States
Here Dr. Steeg describes a drug developed for lung fibrosis with promising implications for metastatic breast cancer. The original developer, Amira, was boug...
Patricia S Steeg 1. Affiliation. 1 Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute Building 37, Room 1122, National Institutes of Health, Bethesda, Maryland 20892, USA. steegp@mail.nih.gov. PMID: 16892035. DOI: 10.1038/nm1469. No abstract available. Publication types.
Patricia S. Steeg. Metastasis is the leading cause of cancer patient mortality. Metastasis suppressors are genes that, upon reexpression in metastatic tumor cells to levels observed in their...
